Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Hodgkin Disease Clinical Trial

— BV-ICE  

Official title:

Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02686346
• Other study ID #: BV-ICE
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 2016
• Est. completion date: July 12, 2021

Study information

• Verified date: December 2021
• Source: The Lymphoma Academic Research Organisation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed as a phase Ib/II trial. The first part (phase Ib) is a dose escalation design to explore the safety and assess the recommended phase 2 dose of Brentuximab Vedotin in Hodgkin lymphoma patients treated with ICE regimen.

The second part, depending on the selected dose after the completion of phase Ib part of the study, will further explore safety in addition to efficacy of the recommended dose of Brentuximab Vedotin in a selected population of patients treated with ICE with Hodgkin lymphoma.

Description:

PHASE I:

3 cycles of Brentuximab Vedotin ICE every 3 weeks and one cycle of Brentuximab Vedotin alone at the doses described below.

Cohorts of between three and six evaluable patients will be recruited at each dose level.

Dose escalation rules:

Treat 3 patients at level K

1. If 0 patients experience dose-limiting toxicity (DLT), escalate to dose K+1

2. If 2 or more patients experience DLT, de-escalate to level K-1

3. If 1 patient experiences DLT, treat 3 more patients at dose level K A. If 1 of 6 experiences DLT, escalate to dose level K+1 B. If 2 or more of 6 experiences DLT, de-escalate to level K-1 Dose escalation will begin at level K.

Level K:

Brentuximab Vedotin: 1.2 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

Level K -1:

Brentuximab Vedotin: 0.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

Level K +1:

Brentuximab Vedotin: 1.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

Dose finding rule:

Provisional dose levels are listed in previous tables. Dose-escalation will continue until Maximal Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is reached or the full doses of BV and ICE are delivered without DLT

PHASE II:

3 cycles of Brentuximab Vedotin + ICE every 3 weeks and one cycle Brentuximab Vedotin alone.

The recommended dose of BV and ICE will be determined by the phase I Brentuximab Vedotin: MTD mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2) The recommended dose of BV and ICE will be determined by the phase I.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: July 12, 2021
• Est. primary completion date: October 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed cluster of differentiation antigen 30 + (CD30+) HL, primarily refractory to first line chemotherapy or in first relapse after any polychemotherapy regimen

• Measurable disease defined as at least one single node or tumor lesion on CT scan > 1.5 cm

• Fluorodeoxyglucose (FDG)-PET/ CT realized at relapse and positive.

• Age = 18 years and up to 65 years

• Eastern Cooperative Oncology Group (ECOG) Performance Status = 2 (see appendix 19.5)

• Life expectancy of > 3 months with treatment

• No major organ dysfunction, unless HL-related

• Normal cardiac and pulmonary function for auto transplantation

• Total bilirubin < 1.5 x ULN (unless due to lymphoma involvement of the liver or a known history of Gilbert's syndrome)

• Alanine aminotransferase/aspartate aminotransferase (ALT/AST) = 2 x ULN (unless due to lymphoma involvement of the liver : = 5 x ULN)

• Creatinine clearance > 60 mL/min

• Absolute neutrophil count = 1.5x109/L, unless caused by diffuse bone marrow infiltration by the HL

• Platelets = 100x109/L, unless caused by diffuse bone marrow infiltration by the HL

• Hemoglobin must be = 8g/dL

• Written informed consent

• Able to adhere to the study visit schedule and other protocol requirements

• Eligible for high dose chemotherapy and autologous peripheral blood stem cell transplantation

• Resolution of toxicities from first-line therapy

• Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.

• Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.

Exclusion Criteria:

• Peripheral sensory or motor neuropathy grade = 2

• Any chemotherapy, radiotherapy, immunotherapy or investigational, therapy for treatment of lymphoma within 28 days prior Cycle1 Day1

• Patient who have been treated by first line of treatment with brentuximab vedotin alone or in combination

• Female patients who are both lactating and breast feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test 4 days prior the start of study drug

• Patients with active, uncontrolled infections (requiring systemic antibiotics within two weeks prior to treatment)

• Prior history of another cancer unless the subject has been free of the disease for = 3 years (with the exception of non-melanoma skin cancer, completely resected melanoma TNMpT1 or carcinoma in situ of the uterine cervix)

• Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of Progressive multifocal leukoencephalopathy

• Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.

• Known history of human immunodeficiency virus (HIV), or known active Hepatitis C Virus, or active Hepatitis B Virus (HBV) infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.

• Patients with a psychiatric disorder that would preclude compliance with drug delivery

• Patients who have any severe and/or uncontrolled medical condition or other conditions that could affect their participation in the study such as:

1. unstable angina pectoris, symptomatic congestive heart failure (NYHA II, III, IV), myocardial infarction = 2 years prior to first study drug administration, serious uncontrolled cardiac arrhythmia, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities

2. cerebrovascular accident = 6 months before study drug start recent evidence (within 6 months before first dose of study drug)

3. a left-ventricular ejection fraction <50%

4. severely impaired pulmonary function as defined as spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) that is 50% or less of the normal predicted value and/or O2 saturation that is 90% or less at rest on room air

5. any active (acute or chronic) or uncontrolled disorders that impair the ability to evaluate the patient or for the patient to complete the study

6. any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose

7. nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by this study drug, such as severe hypertension that is not controlled with medical management and thyroid abnormalities when thyroid function cannot be maintained in the normal range

Related Conditions & MeSH terms

• Hodgkin Disease

Intervention

Drug:
• Brentuximab Vedotin
Phase I: Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Phase II: BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I
• Etoposide
100 mg/m² Days 1-2-3 of Cycles 1-2-3
• Carboplatine
max 800mg Day 2 of Cycles 1-2-3
• Ifosfamide
5 g/m² Day 2 of Cycles 1-2-3

Locations

Country	Name	City	State
Belgium	Clinique Universitaire Saint-Luc	Bruxelles
Belgium	CHU Dinant Godinne	Yvoir
France	Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre	Caen
France	APHP-Hôpital Henri Mondor	Créteil
France	CHU de Dijon - Hôpital le Bocage	Dijon
France	CHRU Lille - Hôpital Claude Huriez	Lille
France	Centre Léon Bérard	Lyon
France	CHU Saint Eloi	Montpellier
France	CHU De Nantes	Nantes
France	Hôpital Necker	Paris
France	APHP - Hôpital Saint Louis	PARIS Cedex 10
France	CHU Lyon Sud	Pierre Bénite Cedex
France	CHU de Poitiers - Hôpital de La Milétrie	Poitiers
France	CHU De Rennes	Rennes
France	Centre Henri Becquerel	Rouen
France	CHU De Strasbourg	Strasbourg
France	IUCT Toulouse	Toulouse
France	CHU De Nancy - Hôpital Brabois	Vandœuvre-lès-Nancy
France	Institut Gustave Roussy	VILLEJUIF Cedex

Sponsors (2)

Lead Sponsor	Collaborator
The Lymphoma Academic Research Organisation	Millennium Pharmaceuticals, Inc.

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I : Maximal Tolerated Dose (MTD) determination	To determine the MTD and/or Recommended Phase II dose (RP2D dose) of BV when administered to adult patients treated with ICE in refractory or relapsed Hodgkin's lymphomas.	4 months
Primary	Phase II = fraction of responding patients according to Lugano classification (metabolic Complete Response)	To evaluate the efficacy of BV in patient treated with ICE as first salvage treatment (establish the fraction of responding patients - metabolic Complete Response (CR)) as judged by the center by Lugano classification after the second cycle	2 months
Secondary	Phase I : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03	To characterize the safety and tolerability of BV in patient treated with ICE.	4 months
Secondary	Phase I = Preliminary Overall Response Rate (ORR)	To assess preliminary anti-tumor activity of BV in patient treated with ICE.	4 months
Secondary	Phase II = ORR	To assess the ORR (Complete Response and Partial Response) after 3 cycles of BV and ICE and one cycle of BV	4 months
Secondary	Phase II : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03	To assess the toxicity profile of BV in patient treated with ICE	4 months
Secondary	Phase II = number of patients with hematological recovery after each cycle	To assess hematological recovery after each cycle of BV and ICE	4 months
Secondary	Phase II = Feasibility of Autologous Stem Cell Transplant (ASCT) after BV-ICE = fraction of patients for whom harvest is possible	To assess the feasibility of harvesting an autologous peripheral blood stem cell graft after BV in patient treated with ICE	4 months
Secondary	Phase II = Fraction of patients eligible for ASCT	To assess the fraction of patients (Complete Response/Partial Response) eligible for ASCT who actually underwent one or two ASCT	4 months
Secondary	Phase II = Number of patients Positron Emission Tomography (PET) 4- after PET 2+	To assess the number of patients with PET 4 negative if the PET 2 is positive	4 months
Secondary	Phase II = Progression Free Survival (PFS)	Number of participants who did not progressed after 2 years	2 years
Secondary	Phase II = Overall Survival (OS)	Number of participants alive after 2 years	2 years